Related Experiment Video
Updated: Jun 15, 2026
08:01
Measurement of Insulin- and Contraction-Stimulated Glucose Uptake in Isolated and Incubated Mature Skeletal Muscle from Mice
Published on: May 16, 2021
AMPK activators as novel therapeutics for type 2 diabetes
Li-Fang Yu1, Bei-Ying Qiu, Fa-Jun Nan
1Chinese National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 189 Guoshoujing Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China.
Current Topics in Medicinal Chemistry
|February 26, 2010
Summary
AMP-activated protein kinase (AMPK) activation offers therapeutic potential for metabolic diseases like obesity and type 2 diabetes by improving glucose uptake and fat metabolism. This review highlights recent advancements in discovering novel AMPK-activating agents.
Area of Science:
- Biochemistry
- Metabolic pathways
- Pharmacology
Background:
- AMP-activated protein kinase (AMPK) is a crucial cellular energy sensor.
- Dysregulation of AMPK is implicated in metabolic diseases such as obesity and type 2 diabetes.
- Targeting AMPK presents a promising therapeutic strategy for metabolic disorders.
Purpose of the Study:
- To review recent advancements in the discovery of novel therapeutic agents that activate AMPK.
- To discuss the mechanisms by which these agents modulate AMPK activity.
- To explore the potential of AMPK activators in treating metabolic diseases.
Main Methods:
- Literature review of recent scientific publications.
- Analysis of studies investigating AMPK activators.
- Synthesis of information on the pharmacological effects of AMPK-targeting agents.
Main Results:
- AMPK activation influences multiple metabolic processes, including glucose uptake, fatty acid oxidation, and mitochondrial biogenesis.
- Numerous compounds have been identified that activate AMPK directly or indirectly.
- These agents demonstrate potential for managing obesity and type 2 diabetes.
Conclusions:
- AMPK remains a significant therapeutic target for metabolic diseases.
- Ongoing research is yielding novel agents with potential clinical applications.
- Further investigation into AMPK-activating therapies is warranted for metabolic health improvement.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:25cAMP-dependent Protein Kinase Pathways
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...